Researchers at Charité – Universitätsmedizin Berlin have demonstrated the potential for using THC, the psychoactive component in cannabis, to treat or even eliminate debilitating nightmares associated with post-traumatic stress disorder (PTSD).

The researchers behind the findings said that THC did not reduce other PTSD symptoms, such as the condition’s severity or depression. However, they plan to further explore its ability to treat nightmares, including the potential safety and efficacy associated with long-term use.

PTSD Nightmares Cause Sleep Deprivation and Fear of Going to Sleep

According to a statement from the Charité team, people who survive or witness extreme experiences such as abuse, war, disasters, or other acts of violence can become overwhelmed and unable to consciously process their experience. As a result, many experience what researchers term an “echo,” where the subconscious tries to process the trauma. The more common term for the experience is post-traumatic stress disorder, or PTSD.

People suffering from this condition often report nightmares as one of the most persistent and debilitating symptoms. Along with the horror associated with continuously reliving their traumas, sometimes on a nightly basis, sufferers also experience severe sleep deprivation. These problems are then compounded by a fear of going to sleep and experiencing nightmares repeatedly.

Attempts to treat PTSD related nightmares have found mixed results. For example, some doctors have prescribed antidepressants or blood pressure-lowering medications to treat the symptoms. However, the research team notes that pharmacological treatments are only partially effective, and “often fail to adequately relieve” PTSD-related nightmares.

There is one medication specifically approved for treating PTSD-induced nightmares. However, the team notes, it is not yet widely available, including in Germany where the study was performed. 

Exploring Alternative Treatments

To explore alternative treatment solutions, Prof. Stefan Röpke, who conducts research on trauma-related disorders at the Department of Psychiatry and Neurosciences on the Benjamin Franklin Campus of Charité, and colleagues designed experiments around tetrahydrocannabinol, or THC.

Although widely used for recreational purposes, cannabis has shown some promise for treating a wide variety of medical and psychological conditions. Still, until recently, the drug’s legal status has limited its medical applications, offering researchers a potentially untapped source of PTSD nightmare relief.

For this study, Professor Röpke and colleagues were interested in THC’s established interactions with the human body’s endocannabinoid system. That’s because this system plays a role in sleep regulation, stress, and the processing of emotional memories.

For example, the professor explained, some evidence suggests that THC reduces activity during REM sleep. Known as the dream state, REM sleep is an intense dream phase during which “the brain processes experiences and regulates emotions.

“THC reduces dream activity and thereby alleviates nocturnal stress responses,” the professor explained.

More Than a Third Report Complete Elimination of Nightmares

To start, the team enlisted more than 170 study participants. Critically, all participants suffered from PTSD and intense nightmares, resulting in sleep deprivation and a fear of going to sleep. Instead of smoking cannabis, the researchers administered a form of cannabis-derived THC drops called Dronabinol. As a legal medication, this form of THC is considered clinically safe.

During the ten-week study period, each participant was instructed to take the drops before bedtime. Half of the participants received THC drops, while the others received cannabis-flavored placebo drops. To maintain double-blind study integrity, neither the participants nor the researchers knew who received which treatment.

After the trial period finished, the researchers discovered several positive results. Most notably, the THC group reported a significant decrease in nightmares compared to the placebo group.

According to the study authors, when ranking a participant’s “nightmare burden” on a scale of zero to eight points, participants’ scores dropped by an average of 3.7 points. For comparison, the placebo group experienced an average drop of 2.2 points.

Perhaps even more significant, Professor Röpke said that “more than a third” of the THC patients reported a complete absence of nightmares after the ten-week period concluded. The professor also noted that 21 percent of the study participants reported that their nightmare burden had been at least cut in half. Finally, the professor said that five out of six study participants in the THC group “felt their health had markedly improved.”

Exploring the Safety and Efficacy of Long-Term THC Use

Although the study results offer some possible hope for relief from nightmares and improved sleep, the researchers said the THC treatments did not affect all PTSD symptoms. For example, they observed that a participant’s PTSD severity and any accompanying depression “did not change conclusively.”

No severe side effects were reported by the THC group. However, the researchers did observe some minor complaints, such as headaches, dizziness, or increased appetite. Participants did not report any withdrawal symptoms after the cessation of the treatment period.

Moving forward, the team will explore the safety and effectiveness of long-term nightly THC treatments. They also hope to explore whether patients develop a tolerance to THC’s nightmare-abating effects over time.

The study “Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial” was published in Nature Medicine.

Christopher Plain is a Science Fiction and Fantasy novelist and has spent the last six years as Associate News Editor and Head Science Writer at The Debrief. Follow and connect with him on X, learn about his books at plainfiction.com, or email him at christopher@thedebrief.org

Frequent cannabis use was associated with higher cortisol upon waking, suggesting a possible disruption of daily stress rhythms. The body’s stress system follows a daily rhythm, and frequent cannabis users may begin that cycle differently. Research from Oregon State University found that people who use cannabis often wake with higher cortisol levels than nonusers, pointing [...]

Ancient enzymes reveal how evolution shaped cannabis chemistry, and how scientists may harness it.

Researchers explored the links between the adolescent dopamine system and cannabis use frequency, amount and addiction severity. A new

In recent years, the global landscape of cannabis policy has undergone significant transformations, stirring complex debates about the implications of legalization, decriminalization, and commercial sales on public health and societal well-being. A comprehensive study published in The Lancet Psychiatry on June 17, 2026, provides the most extensive analysis to date of international cannabis policies and their associations with cannabis use, cannabis use disorder, and other psychiatric outcomes. Led by an interdisciplinary team spearheaded by experts from the University of Bath in the UK, this systematic review draws on a wealth of data spanning across continents including the Americas, Europe, Africa, Australia, New Zealand, and Asia, elucidating the nuanced consequences of various regulatory approaches to cannabis.

The study underscores a critical distinction between policy frameworks that decriminalize or tightly regulate cannabis and those that permit large-scale commercial sales. Decriminalization typically involves removing criminal penalties for personal possession while maintaining restrictions on production and distribution. The data shows that such approaches do not generally lead to an uptick in cannabis consumption. Conversely, jurisdictions that have embraced fully commercialized cannabis markets—with broad retail availability and significant profit-driven incentives, such as many US states and Canada—experience higher consumption rates. These markets tend to propel an increase not just in use, but also in cannabis potency and the prevalence of addiction, revealing troubling public health ramifications hitherto underestimated.

Uruguay’s pioneering legalization model exemplifies a tightly regulated framework. Since its inception, Uruguay has implemented strict controls, limiting cannabis products’ availability and potency, distributing through pharmacy networks, cannabis social clubs, and permitting personal cultivation under strict rules. This structure, focused on harm minimization rather than commercial proliferation, correlates with relatively stable cannabis use rates. Such regulatory restraint contrasts sharply with the dynamics in North America, where deregulation has coincided with escalating rates of daily cannabis consumption and a worrying rise in addiction rates. Notably, in the US, the number of daily cannabis consumers now surpasses daily alcohol consumers, a landmark shift underlining the profound public health challenges precipitated by commercial legalization.

The study identifies the expansion of the for-profit cannabis industry as a pivotal factor in increasing health risks. Mirroring patterns observed historically with tobacco and alcohol industries, large-scale cannabis corporations emphasize product innovation, marketing, and aggressive sales strategies. This has catalyzed the availability of increasingly potent cannabis products, which significantly elevates the risk of dependence and the likelihood of adverse psychiatric outcomes, including psychotic disorders. Furthermore, the surge in hospital admissions due to cannabis-related psychosis in regions with commercial cannabis markets casts a serious shadow over the narrative that legalization inherently reduces harm.

In contrast, decriminalization policies appear to offer a more balanced approach, mitigating the harms associated with criminal prosecution—especially in marginalized communities disproportionately affected by enforcement—while not necessarily increasing use. The researchers highlight this as a crucial insight with implications for evolving policy debates, such as those unfolding in the United Kingdom. Here, cannabis remains a Class B controlled substance with severe penalties, although prominent calls for reform, like the 2025 London Drugs Commission report, advocate for shifting possession offenses away from the criminal justice system toward healthcare frameworks, aiming to reduce social and racial inequities.

Medical cannabis, a rapidly expanding sector, emerged as another focal concern within the study. Regulations remain highly inconsistent globally, and often poorly governed, raising critical questions about safety and therapeutic efficacy. The evidence base, as reviewed in the study, remains inconclusive or limited for many medical indications, especially psychiatric disorders. Despite increasing prescriptions of cannabinoids to treat conditions such as insomnia, autism traits, or substance use disorders, outcomes from randomized clinical trials suggest only modest benefits and lack robust evidence to support claims for efficacy in anxiety, PTSD, depression, or psychosis management. Moreover, unregulated medical cannabis access may inadvertently increase risks of harm due to insufficient clinical oversight and dosage control.

A significant aspect of the analysis relates to cannabis’ psychiatric implications beyond addiction. While daily use has been found to synergistically interact with other risk factors to elevate psychosis risk, the associations with depression, anxiety, and suicidality remain equivocal and warrant further investigation. This nuanced understanding challenges oversimplified narratives around cannabis as either categorically harmful or benign and underscores the critical need for targeted, evidence-based public health interventions.

Professor Tom Freeman, lead author from the University of Bath’s Department of Psychology, emphasizes the decisive role of policy modality over the mere presence of policy changes. He asserts that decriminalization or strict legal regulation can disentangle the harms of criminalization from those stemming from increased cannabis availability and potency. By contrast, commercialized legalization prioritizes market expansion, often at the expense of public health safeguards, exacerbating addiction, and psychiatric morbidity.

The research team also notes a geographical research gap, as much existing evidence centers on North America. They advocate for expanded studies in diverse contexts to fully capture the global ramifications of shifting cannabis policies. Such comprehensive surveillance is vital as an increasing number of countries contemplate or implement reforms, thus influencing future public health trajectories internationally.

The robustness of the conclusions stems from the study’s systematic review methodology, synthesizing findings from numerous epidemiological investigations, clinical trials, and policy analyses. This integrative approach provides a panoramic yet detailed picture of cannabis policy consequences, supporting evidence-based policymaking in a politically charged and rapidly evolving arena.

As cannabis policies continue to evolve worldwide, this landmark study serves as a clarion call for caution, nuanced regulation, and rigorous scientific evaluation. In balancing decriminalization and legal regulation against the risks posed by unbridled commercial markets, policymakers face complex trade-offs with profound implications for population health and social justice.

Subject of Research: Cannabis policies and their effects on cannabis use, addiction, and psychiatric disorders in human populations.

Article Title: International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders published in The Lancet Psychiatry

News Publication Date: 17-Jun-2026

Web References:
The Lancet Psychiatry Article

References:
Systematic review published in The Lancet Psychiatry, 2026

Keywords: Cannabis policy, legalization, decriminalization, cannabis addiction, psychosis, psychiatric disorders, commercial cannabis markets, public health, medical cannabis, cannabis potency, substance use disorder

In recent years, the landscape of cannabis consumption has undergone a significant transformation, with edible cannabis products rapidly gaining popularity among adult consumers. Unlike traditional cannabis forms such as smoking or vaping, edibles—ranging from gummies and chocolates to beverages—often resemble familiar and colorful snacks commonly found in grocery stores. This resemblance, while appealing to adult users, raises concerns about the inadvertent attraction of underage consumers to these products, posing a complex challenge for regulators who aim to restrict youth access while ensuring legal adult availability.

A pioneering study conducted by Washington State University shines a critical light on this issue. The research specifically examines how design elements of cannabis edible packaging, even when compliant with stringent state regulations, may still captivate the attention of teenagers and young adults under the legal age limit. Involving a sample of 454 participants aged between 13 and 20, the study revealed that over 80% of these young individuals found certain cannabis products—particularly gummies and candies—intriguingly appealing, despite the packaging adhering to Washington State’s current legal standards.

This research builds substantially on prior work that indicated adolescents’ favorable perceptions of cannabis edibles stemmed largely from their resemblance to everyday snacks and health food items. What differentiates the current study is its granular analysis of specific visual cues within the packaging that drive youth appeal. Funded by Seattle & King County Public Health and the Washington State Liquor and Cannabis Board, the investigation deployed innovative visual attention tracking methodologies to decipher exactly which features commanded the gaze and interest of the younger demographic.

The methodology involved surveying two distinct age groups: 149 teenagers aged 13 to 17 and 305 young adults aged 18 to 20. Participants were shown high-resolution images of five cannabis edible products legal in Washington State, spanning categories such as gummies, chocolates, pretzels, candies, and cannabis-infused sodas. Using hotspot analysis—where participants clicked on packaging areas they found most captivating—the researchers obtained precise data pinpointing the predominant design characteristics that ignited youthful curiosity and interest.

Analyzing the aggregated data revealed a strong predilection towards colorful logos, prominently displayed brand names, bold typography, and graphical elements mimicking familiar food imagery. These features dominated visual attention, far surpassing regulatory-mandated components like warning labels, ingredient lists, and nutritional information, which attracted minimal engagement from younger viewers. This disparity underscores the profound influence of branding aesthetics over informative content in shaping youth perceptions.

One particularly illuminating discovery pertained to the power of logos and brand identity. Despite compliance with existing regulations, certain branding elements resonated strongly with the youth cohort. A notable example is the turtle logo on a cannabis chocolate package, which, although meeting all state packaging requirements, was repeatedly highlighted by participants as an eye-catching feature. This finding calls into question the sufficiency of current regulations in mitigating youth appeal derived from brand-associated imagery.

Researchers emphasized that branding plays a pivotal role in how adolescents interpret packaging designs. According to Jessica Fitts Willoughby, a professor involved in the study, teenagers often do not distinguish between various package design elements and the intrinsic identity of the brand itself. Instead, they interpret logos, colors, and symbolic images as features that potentially appeal to underage users, complicating regulatory efforts aimed at limiting youth attraction solely through prohibiting overtly child-oriented design elements.

Washington State regulations already prohibit cartoons and bubble-letter fonts on cannabis product packaging to reduce youth appeal. However, the study’s data demonstrated that participants frequently identified colorful logos, playful fonts, and other visually dynamic branding features as appealing, even when these aligned with regulatory frameworks. This suggests an evolving understanding among underage consumers that the allure of branding can transcend explicit design prohibitions, highlighting a critical regulatory grey area.

This issue mirrors historical regulatory challenges faced in the tobacco industry, where decades ago, companies employed cartoon mascots such as Joe Camel to market cigarettes, sparking public health backlash. The eventual removal of such imagery resulted from concerns that these mascots disproportionately attracted children. While cannabis regulations have already banned cartoons, the current findings indicate that subtler branding cues may sustain youth interest despite such restrictions, necessitating a nuanced regulatory reassessment.

Lead author Stacey J.T. Hust points to a disconnect between regulator expectations and adolescent interpretations of packaging visuals. The research suggests that regulatory language is not fully capturing the nuanced way adolescents process visual stimuli on cannabis packages. A more informed regulatory approach would integrate adolescent perspectives, ensuring that interpretations of “youth-appealing” packaging align with how these products are genuinely perceived by underage individuals.

The findings hold profound implications for future regulatory policy development and public health strategies. By incorporating youth feedback into regulatory design criteria, policymakers can better anticipate and address visual elements that sustain youth interest while preserving adult consumer access. This balance is crucial for minimizing unintentional underage cannabis exposure and consumption without curtailing the legal adult market.

Furthermore, the study advocates for ongoing dialogue between researchers, regulators, and youths to continuously refine the understanding of how cannabis packaging influences youth behavior. Such collaboration will be vital as the legal cannabis marketplace evolves, ensuring that prevention efforts remain adaptive and effective in mitigating risks associated with youth appeal.

In summary, this Washington State University study underscores the complex interplay between cannabis packaging design and youth perception. Despite compliance with state regulations intended to reduce youth appeal, specific branding and design attributes continue to attract significant attention from underage demographics. This calls for a sophisticated reevaluation of packaging standards—one that incorporates adolescent perspectives and adopts a scientifically informed approach to limit the inadvertent allure of cannabis edibles to minors.

---

Subject of Research: Youth perception of cannabis edible packaging design and regulatory implications.
Article Title: Appealing to Whom? Identifying Design Features on Cannabis Edible Packaging That Attract Underage Consumers.
News Publication Date: 9 June 2026.
Web References: DOI:10.1016/j.drugpo.2026.105355
References: International Journal of Drug Policy.
Keywords: Cannabis edibles, youth appeal, packaging design, branding, regulatory compliance, adolescent perception, public health, visual attention, hotspot analysis.

Hurty words on social media will bring the police to your door. But when a landlord discovered a cannabis farm in her property, officers didn't want to know. Welcome to two-tier Britain.

The post I Discovered a Cannabis Farm in My Property – and the Police Did Nothing appeared first on The Daily Sceptic.